The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Gene therapy could offer ‘one-time genetic tune-up’ for Alzheimer’s patients

No one knows for certain what causes Alzheimer’s disease. But one fact about the condition has gained nearly irrefutable status. Depending on what versions of a gene called APOE you inherit, your risk of the brain disorder can be half the average—or more than 12 times as high.

Sometimes called “the forgetting gene,” APOE comes in three common versions, called 2, 3, and 4. Type 2 lowers a person’s risk, 3 is average, and 4 increases the chance dramatically.

There’s no cure, and you can’t change your genes, either.

Well, today you can’t. But doctors in New York City say that beginning in May [2019], they will start testing a novel gene therapy in which people with the unluckiest APOE genes will be given a huge dose to their brain of the low-risk version.

Related article:  Genetics for public health: A lost cause?

If that slows the brain-wasting illness in people who already have Alzheimer’s, it could eventually lead to a way to prevent the disease.

Eventually, the hope is, middle-aged people with risky genes might undergo one-time genetic tune-ups. Even a small reduction in the pace at which brain changes occur could make a difference over time.

Read full, original post: Doctors plan to test a gene therapy that could prevent Alzheimer’s disease

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend